NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE announced a quarterly dividend on Tuesday, February 4th. Stockholders of record on Friday, February 14th will be paid a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Thursday, February 13th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings results on Tuesday, February, 4th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.13 by $0.05. The biotechnology company had revenue of $184.93 million for the quarter, compared to analyst estimates of $191.34 million. BIO-TECHNE had a net margin of 26.20% and a return on equity of 12.45%. The company's quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 EPS. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIO-TECHNE.

8 brokerages have issued 12 month price objectives for BIO-TECHNE's shares. Their forecasts range from $225.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $238.33 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

News coverage about TECH stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIO-TECHNE earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in January. As of January 31st, there was short interest totalling 485,700 shares, an increase of 16.2% from the January 15th total of 418,000 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is currently 3.9 days. Approximately 1.3% of the company's stock are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), NVIDIA (NVDA), General Electric (GE), Global Medical REIT (GMRE), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Ionis Pharmaceuticals (IONS).

BIO-TECHNE's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bamco Inc. NY (4.00%), Janus Henderson Group PLC (3.17%), Mairs & Power INC (2.62%), Jackson Square Partners LLC (2.56%), State Street Corp (2.33%) and Champlain Investment Partners LLC (2.26%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, First Trust Advisors LP, Janus Henderson Group PLC, Renaissance Technologies LLC, Schroder Investment Management Group, AQR Capital Management LLC, Bamco Inc. NY and Mairs & Power INC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Jackson Square Partners LLC, Candriam Luxembourg S.C.A., Candriam Luxembourg S.C.A., Geode Capital Management LLC, Champlain Investment Partners LLC, Man Group plc and Thrivent Financial for Lutherans. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $206.03.

BIO-TECHNE has a market capitalization of $7.90 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]